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Available online 28 December 2016Background: Non-obstructive coronary artery disease (CAD) identiﬁed by coronary computed tomography angi-
ography (CCTA) demonstrated prognostic value. CT-adapted Leaman score (CT-LeSc) showed to improve the
prognostic stratiﬁcation. Aim of the studywas to evaluate the capability of CT-LeSc to assess long-term prognosis
of patients with non-obstructive (CAD).
Methods: From 17 centers, we enrolled 2402 patients without prior CAD history who underwent CCTA that




19D. Andreini et al. / International Journal of Cardiology 231 (2017) 18–25into a group without CAD and a group with non-obstructive CAD (b50% stenosis). Segment-involvement score
(SIS) and CT-LeSc were calculated. Outcomes were non-fatal myocardial infarction (MI) and the combined
end-point of MI and all-cause mortality.
Results: Patient mean age was 56 ± 12 years. At follow-up (mean 59.8 ± 13.9 months), 183 events occurred (53
MI, 99 all-cause deaths and 31 late revascularizations). CT-LeScwas the onlymultivariate predictor ofMI (HRs2.84
and 2.98 in two models with Framingham and risk factors, respectively) and of MI plus all-cause mortality (HR
2.48 and 1.94 in twomodels with Framingham and risk factors, respectively). This was conﬁrmed by a net reclas-
siﬁcation analysis conﬁrming that the CT-LeSc was able to correctly reclassify a signiﬁcant proportion of patients
(cNRI 0.28 and 0.23 for MI and MI plus all-cause mortality, respectively) vs. baseline model, whereas SIS did not.
Conclusion: CT-LeSc is an independent predictor of major acute cardiac events, improving prognostic stratiﬁcation
of patients with non-obstructive CAD.






In recent years, studies supporting the prognostic value of coronary
CT angiography (CCTA), including single-center studies and a large mul-
ticenter registry, have been published [1,2]. According to these data,
while the absence of identiﬁable plaques in the coronary tree is associat-
edwith an excellent prognosis, it has also been consistently demonstrat-
ed that the identiﬁcation of non-obstructive lesions, a unique feature of
CCTA as a non-invasive coronary imaging modality, has prognostic
value. This has clinical implications becausemany patients fall in this cat-
egory, as reﬂected by the high proportion of patientswith atherosclerotic
plaques in many CCTA databases [2–5]. Nevertheless, as non-obstructive
CAD is a very heterogeneous and prevalent condition, there is the need
for tools to quantify total coronary atherosclerotic burden in order to bet-
ter stratify these patients. Recently, a new developed score, the CT-
adapted Leaman score (CT-LeSc), using the comprehensive information
on lesion localization, plaque composition and degree of stenosis provid-
ed by CCTA, resulted in a relatively small, single-center setting, to be an
independent long-term predictor of hard cardiac events and to improve
the CCTA prognostic stratiﬁcation of non-obstructive CAD [6].
In the present prospective international multicenter study, we eval-
uated the capability of the CT-LeSc to stratify the long-term prognosis of
a large cohort of patients with non-obstructive CAD at CCTA evaluation.
2. Methods
2.1. Study population
The design and rationale of the CONFIRM(COronary CTAngiography
EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) regis-
try has been described previously [7]. For the current study, we utilized
the data from the CONFIRM long-term follow-up registry that included
only patients who had a follow-up duration of more than three years.
Overall, 17,181 patients who underwent CCTA at 17 centers in 9 coun-
tries (Austria, Canada, Germany, Israel, Italy, Portugal, South Korea,
Switzerland, and United States) were enrolled between February 2003
and May 2011 for long-term follow-up. Inclusion criteria were age
N18 years, a CCTA performed with a scanner equipped with at least
64-detectors, and CCTA images of interpretable quality. Among the
5010 patients in whom MACE data at follow-up and complete plaque
characteristics datawere collectedwe excluded thosewith prior history
of CAD (n= 1741), myocardial revascularization performed early after
CCTA (b90 days) (n = 377) and presence of obstructive coronary le-
sions (N50%) (n= 490). The analytic sample comprised 2402. patients.
Informed consentwas obtained fromeach patient and [2] the studypro-
tocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by the institution's human re-
search committee.
2.2. Risk factor assessment
Clinical CAD risk factors including smoking, hypertension, dyslipid-
emia, diabetes, and family history were collected prior to CCTAexamination by direct patient interview performed by a physician
or nurse research coordinator and/or with standardized site question-
naires [7].2.3. Imaging analysis
CCTA data were acquired using multi-detector row CT scanners
consisting of 64-rows or greater. Expert readers analyzed all CCTA
images according to the guidelines of the Society of Cardiovascular
Computed Tomography (SCCT) [8,9]. We deﬁned coronary athero-
sclerosis in CCTA images as any tissue structure larger than 1 mm2,
which was either within the lumen of the coronary artery or adja-
cent to the coronary artery lumen and could be distinguished from
the adjacent epicardial fat, pericardial tissue, or the artery lumen.
We used a modiﬁed American Heart Association 16-segment coro-
nary artery tree model for analysis [10]. Coronary artery luminal
narrowing was deﬁned as the presence of any plaque resulting in a
% diameter reduction N0. Non-obstructive lesions were deﬁned as
coronary artery segments showing plaques with a luminal diameter
stenosis b50%. Normal CCTA was deﬁned as the absence of any cor-
onary artery luminal narrowing. The SIS, ranging from 0 to 16, was
calculated as the total number of segments with plaques (any de-
gree of stenosis). The methodology for the CT-LeSc has been previ-
ously described [11]. Brieﬂy, three sets of weighting factors are
used for this score: 1) localization of the coronary plaques, account-
ing for dominance; 2) type of plaque, with a multiplication factor of
1 for calciﬁed plaques and of 1.5 for non-calciﬁed and mixed
plaques; and 3) degree of stenosis, with a multiplication factor of
0.615 for non-obstructive (b50% stenosis) and a multiplication fac-
tor of 1 for obstructive (≥50% stenosis) lesions. The CT-LeSc was cal-
culated on a patient level as the sum of the partial CT-LeSc of all
evaluable coronary segments. For both the SIS and the CT-LeSc,
prognostically validated cut-off values (N5) were used [4,6]. Analy-
sis of coronary artery calcium score was performed when available.
The total mean dose length product for CCTA was estimated to be
938 ± 379 mGy × cm, corresponding to an estimated radiation
dose of 13 ± 5 mSv.2.4. Patient follow-up
The primary outcomes of the current study were non-fatal myocar-
dial infarction (MI) and the combined end-point of MI and all-cause
mortality. As previously reported [7], the outcomes were assessed at
each institution by direct interview, telephone contact, review of medi-
cal records, or using a mailed standardized questionnaire. In the USA,
all-cause mortality was additionally searched by the Social Security
Death Index. Site physicians deﬁned MI according to ACC/AHA guide-
lines and the World Health Organization Universal Deﬁnition of Myo-
cardial Infarction [12]. All revascularizations were recorded and
patients with elective myocardial revascularization were censored at
follow-up.
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Categorical variables are presented as counts and proportions.
Continuous variables are presented as means ± SD. A one-way
ANOVA or the Kruskal–Wallis test was used to conduct continuous var-
iables intergroup comparisons among patients without CAD, non-
obstructive CAD but a LS b 5 and non-obstructive CAD but a LS N 5.
Pearson's chi-square test (χ2) was used for categorical variables com-
parison. Time-to-event analysis for the study endpoints were calculated
using univariable Cox proportional-hazards models reporting hazard
ratios (HR) with 95% conﬁdence intervals (95% CI). Multivariable Cox
proportional hazards models were also constructed with variables
based on clinical judgment univariate analysis results. All the analyses
were performed evaluating combined endpoints (MI, MI plus all cause
of death,). To avoid overﬁtting and multicollinearity issues, we devel-
oped four different models, for all different combined endpoints. The
ﬁrst model was adjusted for the CT-LeSc and the Framingham risk
score. The second model was adjusted for the SIS and the Framingham
risk score. The third model was adjusted for the CT-LeSc and baseline
clinical characteristics. The fourth model was adjusted for the SIS and
baseline clinical characteristics.
A sub-analysis were performed in patients in which CACSwas avail-
able; a prognostically validated cut-off N400 was used as previously
suggested [13]. Moreover we performed a separate sub-analysis for pa-
tients with andwithout chest pain at baseline. Of note, in the analysis of
symptomatic subjects the Morise score was included in model 1 and 2,
instead of the Framingham score.
Survival curves were calculated using the Kaplan–Meier method for
population stratiﬁed by the presence of non-obstructive CAD and the
CT-LeSc, with each survival curve compared using the log-rank test. A
two-tailed p value of b0.05 was considered statistically signiﬁcant. The
comparison between performance of the CT-LeSc and SIS added to a
baseline model was further quantiﬁed by a continuous net reclassiﬁca-
tion index (cNRI) [14].Table 1






Age 56 ± 12 53 ± 12
Male 1208 (50.3) 657 (45.3)
BMI 28 ± 5.49 27.79 ± 5.39
Hypertension 1302 (54.2) 674 (46.5)
Diabetes 252 (10.5) 116 (8)
Current smoking 425 (17.7) 250 (17.2)
Family history 798 (33.2) 492 (33.9)
Dyslipidemia 1207 (50.3) 641 (44.2)
Morise 11.57 ± 4.16 10.70 ± 4.42
Framingham 11.99 ± 9.63 9.74 ± 7.78
Chest pain at baseline
No chest pain 1053 (43.8) 590 (40.7)
Non-cardiac/unspeciﬁed pain 418 (17.4) 296 (20.4)
Atypical chest pain 737 (30.7) 436 (30.1)
Typical chest pain 194 (8.1) 128 (8.8)
Therapy
ASA 503 (20.9) 265 (18.3)
Statin 506 (21.1) 226(15.6)
CCTA characteristics
SIS 1.08 ± 1.89 0
Continuous variable are expressed asmean±SD;Ordinal variables are expressed as n (%); BMI:
disease.
⁎ p b 0,0001 vs no CAD.
o p b 0,0001 vs LS b 5.
§ p b 0,05 vs no CAD.
ç p b 0,05 vs LS b 5.3. Results
3.1. Patient characteristics and MACE
Indications for CCTAwere chest pain (1200patients, 49.9%),multiple
CAD risk factors (595 patients, 24.7%), and equivocal or abnormal stress
test results (607 patients, 25.3%). Mean pre-test probability of CAD was
low-to-intermediate (mean Morise score 11.6 ± 4.2). The mean dura-
tion of follow-up was 59.8 ± 13.9 months, up to 96 months (Table 1).
One-hundred and eighty-three patients exhibited events during
follow-up (53 MI, 99 all-cause deaths and 31 late revascularizations).
3.2. Univariate predictors of events
Among clinical characteristics, therapywith aspirinwas the only pre-
dictor of MI, whereas hypertension and diabetes were predictors of MI
plus all-cause death. Among CCTA data, a SIS N 5 and non-obstructive
CAD with a CT-LeSc N 5 were predictors of MI, whereas a SIS N 5, non-
obstructive CAD with a CT-LeSc ≤ 5 and non-obstructive CAD with a
CT-LeSc N 5 were predictors of MI plus all-cause death (Table 2).
3.3. Multivariate predictors of events
The only signiﬁcant independent predictor of MI was non-
obstructive CAD with a CT-LeSc N 5 (HR 2.84 and 2.98 in model 1 and
model 3, respectively). The independent predictors of MI plus all-
cause death were the Framingham score (HR 1.02 and 1.03 in model 1
and model 2, respectively), age (HR 1.04 and 1.05 in model 3 and
model 4, respectively), diabetes (HR 1.84 and 1.86 in model 3 and
model 4, respectively), a SIS N 5 (HR 1.95 in model 2, HR not signiﬁcant
in model 4), non-obstructive CAD with a CT-LeSc ≤ 5 (HR 2.05 and 1.55
in model 1 and model 3, respectively) and non-obstructive CAD with a
CT-LeSc N 5 (HR 2.48 and 1.94 in model 1 and model 3, respectively)
(Table 3).Non-obstructive CAD with
LS ≤ 5 (n= 611)
Non-obstructive CAD with
LS N 5 (n= 341)
61 ± 10⁎ 63 ± 11⁎,ç
346 (56.7)⁎ 205 (60.1)⁎
28.09 ± 5.11 28.61 ± 6.40
394 (64.5)⁎ 234 (68.6)⁎
74 (12.1)§ 62 (18.1)⁎,ç
105 (17,2) 70 (20.53)
188 (30,8) 118 (34.6)
342 (56)⁎ 224 (65.7)⁎,ç
12.68 ± 3.37⁎ 13.19 ± 3.31⁎
14.83 ± 10.46⁎ 16.27 ± 11.98⁎
308 (50.4) 155 (45.4)
79 (12.9) 43 (12.6)
184 (30.1) 117 (34.3)
40 (6.5) 26 (7.6)
137 (22.4)§ 101 (29.6)⁎,ç
161 (26.4)⁎ 119 (34.8)⁎,ç
1.61 ± 0.88⁎ 4.64 ± 2.36⁎,o




MI + all-cause death
HR (95% CI) p HR (95% CI) p
Clinical characteristics
Age 1 (0.98–1.02) 0.871 1.04 (1.02–1.05) b0.0001
Male 0.78 (0.46–1.32) 0.343 1.1 (0.79–1.51) 0.5731
BMI 1.03 (0.99–1.07) 0.128 1.01 (0.98–1.04) 0.596
Hypertension 1.52 (0.87–2.67) 0.143 1.97 (1.39–2.79) b0.0001
Diabetes 1.85 (0.9–3.79) 0.095 1.95 (1.29–2.96) 0.002
Current smoking 1.68 (0.91–3.1) 0.096 1.33 (0.91–1.95) 0.144
Family history 1.46 (0.84–2.52) 0.182 0.86 (0.1–1.23) 0.417
Dyslipidemia 1.17 (0.68–2.01) 0.573 0.9 (0.65–1.24) 0.505
Morise 0.98 (0.92–1.05) 0.629 1.03 (0.99–1.07) 0.168
Framingham 1.01 (0.99–104) 0.366 1.03 (1.02–1.04) b0.0001
Chest pain at baseline
No chest pain 1 1
Non-cardiac pain/unspeciﬁed 1.34 (0.69–2.64) 0.388 0.80 (0.52–1.24) 0.325
Atypical chest pain 0.82 (0.42–1.57) 0.547 0.50 (0.33–0.75) 0.001
Typical chest pain 1.07 (0.41–2.80) 0.886 0.60 (0.31–1.16) 0.130
Therapy
ASA 1.84 (1.01–3.34) 0.046 1.42 (0.98–2.05) 0.063
Statin 1.2 (0.63–2.27) 0.585 1.12 (0.77–1.63) 0.563
CCTA characteristics
SIS N 5 1.13 (1.02–1.26) 0.022 1.18 (1.12–1.25) b0.001
No CAD 1 1
Non-Ob CT-LeSc ≤ 5 1.18 (0.62–2.23) 0.618 1.88 (1.3–2.72) 0.0008
Non-OB CT-LeSc N 5 2.11 (1.11–3.99) 0.023 2.37 (1.58–3.57) b0.001
BMI: bodymass index; SIS: segment involvement score; CT-LeSc: CT-Adapted Leaman Score; Non-Ob: non-obstructive coronary artery disease (stenosis b50%); MI: non-fatal myocardial
infarction; CAD: coronary artery disease.
Table 3
Multivariate analysis.
MI MI + all-cause
death
HR (95% CI) p HR (95% CI) p
Model 1
Framingham 1.01 (0.98–1.04) 0.4316 1.02 (1.01–1.04) 0.0006
ASA 1.51 (0.82–2.77) 0.1860 1.32 (0.91–1.93) 0.1402
Non-Ob CT-LeSc b 5 1.70 (0.84–3.47) 0.1444 2.05 (1.36–3.01) 0.0006
Non-Ob CT-LeSc N 5 2.84 (1.38–5.85) 0.0049 2.48 (1.58–3.90) 0.0001
Model 2
ASA 1.67 (0.91–3.05) 0.0995 1.41 (0.98–2.06) 0.0672
Framingham 1.02 (0.99–1.05) 0.1011 1.03 (1.02–1.04) b0.0001
SIS N 5 0.85 (0.20–3.35) 0.8252 1.95 (1.09–3.49) 0.0244
Model 3
Age 0.99 (0.96–1.02) 0.7768 1.04 (1.02–1.06) b0.0001
Male 0.67 (0.35–1.28) 0.2363 0.91 (0.62–1.34) 0.6515
BMI 0.98 (0.93–1.04) 0.6053 0.99 (0.95–1.02) 0.6837
Hypertension 1.13 (0.57–2.26) 0.7140 1.39 (0.89–2.14) 0.1414
Diabetes 1.41 (0.60–3.32) 0.4242 1.84 (1.13–2.99) 0.0138
Current smoking 1.11 (0.50–2.43) 0.7914 1.42 (0.89–2.26) 0.1342
Dyslipidemia 1.10 (0.57–2.11) 0.7719 0.74 (0.50–1.09) 0.1342
Family history 1.23 (0.65–2.31) 0.5184 1.06 (0.71–1.59) 0.7598
ASA 1.42 (0.73–2.76) 0.2937 1.08 (0.71–1.65) 0.6983
Non-Ob CT-LeSc b 5 1.64 (0.73–3.65) 0.2252 1.55 (0.97–2.45) 0.0627
Non-Ob CT-LeSc N 5 2.98 (1.35–6.58) 0.0070 1.94 (1.18–3.12) 0.0095
Model 4
Age 1.01 (0.98–1.03) 0.5466 1.05 (1.03–1.07) b0.0001
Male 0.79 (0.42–1.49) 0.4813 0.99 (0.68–1.46) 0.9953
BMI 0.98 (0.93–1.04) 0.7247 0.99 (0.95–1.03) 0.7503
Hypertension 1.19 (0.59–2.37) 0.6170 1.46 (0.94–2.25) 0.0900
Diabetes 1.52 (0.65–3.55) 0.3278 1.86 (1.14–3.02) 0.0125
Current smoking 1.20 (0.55–2.64) 0.6413 1.49 (0.93–2.35) 0.0957
Dyslipidemia 1.21 (0.63–2.32) 0.5568 0.77 (0.52–1.13) 0.1878
Family history 1.28 (0.68–2.39) 0.4402 1.08 (0.72–1.61) 0.7032
ASA 1.54 (0.79–2.96) 0.2001 1.13 (0.74–1.72) 0.5560
SIS N 5 0.83 (0.19–3.52) 0.8043 1.38 (0.74–2.56) 0.3083
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When MI only was considered as outcome, the event-free survival
rates were 98% in patients without CAD, 98% in patients with non-
obstructive CAD and a CT-LeSc ≤ 5 and 95% in patients with non-
obstructive CAD and a CT-LeSc N 5 (log-rank p value = 0.01)
(Figure 1A). When the end-point of MI plus all-cause mortality was
used, event-free survival rates were 97%, 92% and 88% in patients
without CAD, with non-obstructive CAD and a CT-LeSc ≤ 5 and
with non-obstructive CAD and a CT-LeSc N 5, respectively (log-rank
p value b 0.0001) (Figure 1B).
3.5. Reclassiﬁcation index
The net reclassiﬁcation analysis (Table 4) showed that a CT-LeSc N 5
is able to correctly reclassify a signiﬁcant proportion of patients (0.28
and 0.23forMI andMIplus all-causemortality, respectively), in compar-
ison with the baseline model including age, male gender, diabetes,
hypertension, smoking, dyslipidemia, and family history of premature
CAD. Conversely, reclassiﬁcation using a SIS N 5 was not statistically sig-
niﬁcant in any models.
3.6. Coronary artery calcium score sub-analysis
Coronary artery calcium score (CACS) was available in 1537 patients
(64%). CACS N 400 was identiﬁed in 67 patients (4.4%) in the entire
cohort; CACS N 400 was present in 6 patients (1.6%) with CT LeSc ≤ 5
and in 61 subjects (22.9%) among those with CT LeSc N 5. At univariate
analysis neither CACS N 400 or SIS N 5 was associated withMI (HR 1.85;
95% CI 0.57–5.98, p=0.306 and 0.89; 0.22–3.68, p=0.896), while only
CT-LeSc N 5 was a signiﬁcantly predictors of MI (HR 2.09; 95% CI 1.02–
4.30, p = 0.04). When the composite endpoint including MI and all
cause of death was considered, CACS N 400, SIS N 5 and CT-LeSc N 5
Fig. 1. Kaplan-Meier survival curves for MI (A) showing the event-free survival rates of 98% in patients with non-obstructive CAD and a CT-LeSc ≤ 5 and 95% in patients with non-
obstructive CAD and a CT-LeSc N 5 (log-rank p value = 0.01). When the end point was MI plus all-cause mortality (B), event-free survival rates were 97%, 92% and 88% in patients
without CAD, with non-obstructive CAD and a CT-LeSc ≤ 5 and with non-obstructive CAD and a CT-LeSc N 5, respectively (log-rank p value b 0.0001). MI: myocardial infarction; CAD:
coronary artery disease; CT-LeSc: computed tomography adapted Leaman score.
22 D. Andreini et al. / International Journal of Cardiology 231 (2017) 18–25were all signiﬁcative predictors of events (HR 3.99, HR2.38 andHR2.73,
respectively; p b 0.001).
At multivariate analysis CACS N 400 remains a signiﬁcantly predictor
ofMI+ all cause of deathwhen adjusted for Framingham risk score (HR
3.04; 95%CI 1.72–5.36, p b 0.001) and for baseline clinical characteristics
(HR 2.05; 95% CI 1.14–3.68, p=0.017); SIS N 5 remains signiﬁcantly as-
sociated toMI+ all cause of death only when adjusted for Framingham
risk score (HR1.96; 95% CI 1.09–3.55, p=0.027), but notwhenadjusted
for clinical baseline characteristics.
Of note, only CT-LeSc N 5was signiﬁcantly associated toMIwhen ad-
justed both for Framingham risk score (HR 2.68; 95% CI 1.18–6.12, p=
0.019) and for baseline clinical characteristics (HR 3.13; 95% CI 1.29–
7.53, p=0.012) at multivariate analysis.When the composite endpoint
including MI + all cause of death was considered CL-LeSc N 5 was still
associated to events both when adjusted for Framingham risk score
(HR 2.52; 95% CI 1.52–4.16, p b 0.001) and for baseline characteristics
(HR 1.79, 95% CI 1.05–3.05, p= 0.038).
In this subgroup of patients with CACS reported, the event free sur-
vival rateswere 98% in thosewith CT-LeSc b 5 and 95% in thosewith CT-
LeSc N 5 (log-rank p=0.0289) (Figure 2B); on the contrary CACS N 400
score was not signiﬁcantly associated to worst survival rates
(Figure 2A).3.7. Asymptomatic patients vs symptomatic patients
Among the entire cohort 1053 patients (43.8%) did not report chest
pain at baseline, while 1349 patients (56.2%) were symptomatic at the
time of CCTA.
A separate sub-analysis in asymptomatic subjects showed that at
univariate analysis there were no predictor of MI; on the contrary,
age, hypertension, diabetes and the Framingham score were the clinical
characteristics associated toMI+all cause of death,while amongCTpa-
rameters both SIS N 5 and CT-LeSc N 5were associated toMI+ all cause
of death (Table 5).Table 4
Net Reclassiﬁcation Index for SIS N 5 and CT-LeSc N 5 for prediction of composite
endpoints.
MI MI + all-cause death
cNRI cNRI 95% CI p cNRI cNRI 95% CI p
BL − − − − − −
BL + SIS N 5 0.15 −0.09–0.40 0.271 −0.039 −0.19–0.11 0.648
BL + CT-LeSc N 5 0.28 0.02–0.54 0.046 0.23 0.07–0.39 0.006In the subgroups of patients with chest pain at baseline only CT-
LeSc N 5 was associated to MI at univariate (HR 2.5; 95% CI 1.13–5.75,
p= 0.025), while age, hypertension and the Morise score were associ-
ated to MI + all cause of death, but only CT-LeSc N 5 (HR 2.53; 95% CI
1.42–4.48, p = 0.002) was found to be associated to this composite
end-point among CCTA variables (Table 6).
At multivariate analysis SIS N 5was not associated to endpoints both
in asymptomatic and symptomatic patients. On the contrary CT-LeSc N 5
was found to be a predictor ofMI in symptomatic patients ( HR 2.63 and
2.76 in Model 1 and 3, respectively) and to be associated with MI + All
cause of death both in asymptomatic and symptomatic patients only
when adjusted for Framingham or Morise score (HR 2.56 and 2.39 in
asymptomatic and symptomatic patients, respectively), but not when
clinical baseline characteristics were evaluated separately (Table 7).
4. Discussion
Coronary CTA has been demonstrated to be accurate for the detec-
tion of non-obstructive CAD and coronary atherosclerosis when com-
pared to coronary intravascular ultrasound [15]. Detection of non-
obstructive CAD, which may be considered an unique feature of CCTA
among other non-invasive imaging modalities, has relevant prognostic
implications. Indeed, it may identify a population that has an higher
event-free survival rate as compared to that of patients with obstructive
disease but lower than that of patients with normal coronaries [4,5,16,
17]. In order to better stratify the prognosis among the large and hetero-
geneous cohort of patients with non-obstructive CAD, different coro-
nary plaque scores have been proposed. Among them, the SIS and SSS
demonstrated a remarkable prognostic value [4,18]. Particularly, a
single-center study by Bittencourt et al. demonstrated that among pa-
tientswith obstructive CAD, a greater extent of non-obstructive plaques,
as quantiﬁed by SIS, was associated with a higher event rate [16].
4.1. CT adapted-Leaman score
A recently proposed plaque score, the CT-LeSc based on lesion local-
ization, plaque composition anddegree of stenosis, demonstrated to im-
prove the prognostic stratiﬁcation of non-obstructive CAD in an another
single-center study [6]. To the best of our knowledge, this is the ﬁrst
prospective international multicenter study ﬁnalized to evaluate if the
CT-LeSc is able to stratify the long-term prognosis in a selected but
large patient cohort with non-obstructive lesions. The main ﬁndings of
the study are that the CT-LeSc allows to distinguish within patients
with non-obstructive CAD those with a cardiac event risk similar to
that shared by patientswithout plaques from thosewith a less favorable
Fig. 2.KaplanMeyer survival curves for MI using CACS (A) and CT-LeSc (B). CACS N 400was not able to stratify patients at higher risk of MI. On the contrary, patients with CT-LeSc N 5was
associated to an event free survival rate of 95%, that was found to be signiﬁcantly lower than patients with CT-LeSc b 5 (log-rank p= 0.0289). MI: myocardial infarction; CACS: coronary
artery calcium score; CT-LeSc: computed tomography adapted Leaman score.
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spite the latter already showed to possess a good prognostic value. In
particular, analyzing the primary outcomes of the study we found that
a CT-LeSc N 5 was an univariate predictor of MI and MI plus all-cause
death and the only multivariate predictor of MI.
4.2. CT-LeSc vs SIS
The CT-LeSc appears to be superior to the SIS that exhibited HR sys-
tematically lower than the CT-LeSc at both univariate and multivariate
analysis. This is conﬁrmed by the net reclassiﬁcation analysis showing
that the CT-LeSc, but not the SIS, was able to correctly reclassify a signif-
icant proportion of patients vs. a baseline model including age, gender
and risk factors for both primary and secondary endpoints.
4.3. CACS and CT-LeSc
In the sub-group of patientswith calciumscore, CACS N 400has been
conﬁrmed to be a predictor of composite end-point including all cause
of death, but only CT-LeSc appeared to correctly identify patients at
higher risk of MI. These ﬁndings could be explained by recent studies,
suggesting that non-calciﬁed plaques may be associated to higher risk
of acute coronary syndrome when compared to calciﬁed ones [19].Table 5
Univariate analysis for asymptomatic patients.
MI
MI + all-cause death
HR (95% CI) p HR (95% CI) p
Clinical characteristics
Age 1.01 (0.98–1.04) 0.578 1.03 (1.01–1.05) 0.001
Male 0.68 (0.31–1.52) 0.356 0.93 (0.60–1.43) 0.717
BMI 1.04 (0.98–1.09) 0.182 1.02 (0.98–1.05) 0.424
Hypertension 1.63 (0.70–3.78) 0.261 1.83 (1.15–2.94) 0.011
Diabetes 1.43 (0.43–4.79) 0.556 2.05 (1.15–3.63) 0.015
Current smoking 0.99 (0.34–2.89) 0.996 0.98 (0.55–1.75) 0.962
Family history 1.26 (0.54–2.93) 0.597 0.77 (0.46–1.29) 0.333
Dyslipidemia 0.62 (0.27–1.42) 0.263 0.67 (0.40–1.01) 0.052
Framingham 0.98 (0.93–1.03) 0.404 1.02 (1.01–1.03) 0.048
Therapy
ASA 1.50 (0.56–3.99) 0.411 1.69 (1.03–2.77) 0.038
Statin 0.70 (0.20–2.40) 0.572 0.97 (0.55–1.72) 0.931
CCTA characteristics
No CAD 1 1
SIS N 5 1.94 (0.46–8.22) 0.367 2.02 (1.06–4.56) 0.034
Non-Ob CT-LeSc ≤ 5 1.12 (0.44–2.85) 0.807 2.11 (1.29–3.42) 0.003
Non-OB CT-LeSc N 5 1.61 (0.56–4.53) 0.376 2.17 (1.22–3.86) 0.0094.4. Asymptomatic and symptomatic patients
Approximately half of the patients included in this study were
asymptomatic for chest pain at the time of CCTA. In order to better clar-
ify the possible role of CCTA in the evaluation of asymptomatic patients
we performed a speciﬁc separate analysis in asymptomatic vs symp-
tomatic patients. Of note we have found no clinical or CCTA parameters
resulting to be signiﬁcantly associated to MI in asymptomatic patients.
On the contrary in symptomatic patients only CT-LeSc N 5 was associat-
ed toMI both at univariate andmultivariate analyses. This ﬁndings sug-
gest that CT-LeSc could be an important tool to discriminate patients at
higher risk of MI among those symptomatic for chest pain, even if CCTA
results to be negative for signiﬁcative stenosis (N50%).4.5. Survival analysis
Analyzing the survival curves for primary endpoints, we found that
MI-free survival ratewas 98% for patientswith normal coronary arteries
and for those with non-obstructive CAD and a CT-LeSc ≤ 5. Conversely,
the survival rate fell to 95% in the presence of a CT-LeSc N 5, conﬁrming
the power of the CT-LeSc in stratifying the prognosis of patients with
non-obstructive lesions. Adding all-causemortality toMI in the survival
analysis, patients with non-obstructive stenosis and a low CT-LeScTable 6
Univariate analysis for symptomatic patients.
MI
MI + All-cause death
HR (95% CI) p HR (95% CI) p
Clinical characteristics
Age 1.01 (0.97–1.03) 0.921 1.04 (1.02–1.07) b0.001
Male 0.86 (0.43–1.74) 0.862 0.74 (0.46–1.22) 0.246
BMI 1.02 (0.95–1.08) 0.641 1.01 (0.96–1.05) 0.754
Hypertension 1.15 (0.57–2.31) 0.696 1.76 (1.06–2.95) 0.031
Diabetes 1.93 (0.9–4.67) 0.149 1.83 (0.98–3.42) 0.059
Current smoking 1.49 (0.67–3.32) 0.323 1.39 (0.79–2.44) 0.249
Family history 1.38 (0.68–2.79) 0.373 1.05 (0.63–1.72) 0.866
Dyslipidemia 1.51 (0.74–3.08) 0.259 1.40 (0.87–2.29) 0.181
Morise 1.01 (0.92–1.09) 0.946 1.08 (1.02–1.16) 0.016
Therapy
ASA 1.82 (0.84–3.93) 0.129 1.18 (0.66–2.08) 0.571
Statin 1.31 (0.59–2.87) 0.513 1.29 (0.76–2.18) 0.354
CCTA characteristics
No CAD 1 1
SIS – – 2.03 (1.01–5.31) 0.051
Non-Ob CT-LeSc ≤ 5 1.20 (0.49–2.92) 0.677 1.43 (0.80–2.57) 0.229
Non-OB CT-LeSc N 5 2.54 (1.13–5.75) 0.025 2.53 (1.42–4.48) 0.002
Table 7
Multivariate analysis for asymptomatic and asymptomatic patients.
MI MI + all-cause death
HR (95% CI) p HR (95% CI) p
Asymptomatic patients
Model 1⁎
Non-Ob CT-LeSc N 5 3.34 (0.97–11.44) 0.059 2.56 (1.31–4.99) 0.006
Model 2⁎
SIS N 5 2.42 (0.55–10.73) 0.248 1.80 (0.82–3.95) 0.144
Model 3§
Non-Ob CT-LeSc N 5 3.15 (0.84–11.78) 0.089 1.50 (0.73–2.94) 0.227
Model 4§
SIS N 5 1.19 (0.26–5.51) 0.821 0.98 (0.41–2.35) 0.967
Symptomatic patients
Model 1#
Non-Ob CT-LeSc N 5 2.63 (1.07–6.46) 0.035 2.39 (1.29–4.42) 0.006
Model 2#
SIS N 5 – – 2.03 (0.85–4.82) 0.110
Model 3§
Non-Ob CT-LeSc N 5 2.76 (1.06–7.25) 0.040 1.81 (0.94–3.51) 0.075
Model 4§
SIS N 5 – – 1.54 (0.64–1.86) 0.807
§ Adjusted for ASA and baseline clinical characteristics.
# Adjusted for ASA and Morise score.
⁎ Adjusted for ASA and Framingham score.
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out plaques and that of patients with a CT-LeSc N 5.
4.6. Future strategies for early detection of non-obstructive CAD
Previous studies have proposed that early identiﬁcation of non-
obstructive CAD with CCTA may lead to a more aggressive strategy to
control cardiovascular risk factors and to improve clinical follow-up [4,
20]. Recently, a sub-study of CONFIRMperformed in a cohort of patients
receiving baseline statin and aspirin treatment showed that statin ther-
apy was associated with a signiﬁcant mortality reduction in patients
with non-obstructive CAD but had no impact on patients without CAD
[18]. These are valid arguments in support of the identiﬁcation of pa-
rameters, such as the CT-LeSc allowing to stratify the long-termprogno-
sis of the large and heterogeneous group of patients in whom CCTA
shows non-obstructive CAD. Moreover, recent studies demonstrated
the prognostic value of plaque characterization by CCTA. Indeed, this
non-invasive imaging modality is able to identify some features, such
as vessel positive remodeling and low-attenuation plaques, that have
been associated with a higher risk of cardiac events [19]. High-risk
plaques can be detected by CCTA and are independent predictors of
fatal and non-fatal acute coronary syndrome,while positive remodeling
has been observed in coronary stenoses that, regardless of the degree of
narrowing, were found to be functionally important by invasive frac-
tional ﬂow reserve [21]. Therefore, additional studies are needed to in-
tegrate the CT-LeSc with other features such as positive remodeling or
eventually with non-invasive FFR by CCTA for improving the prognostic
characterization of patients without obstructive coronary lesions.
4.7. Study limitations
In interpreting these data some limitations should be considered.
First, management decisions in all patient, such as medical therapies
or revascularization, were left to the discretion of the referring physi-
cians. Because some therapies (i.e. aspirin, statin) may have a positive
effect on patient outcomes and were commonly used in patients with
and without plaques, we expect that differences between subgroups
would be even greater in the absence of such treatments. Second,we in-
cluded all-cause mortality in the primary and secondary endpoints
given its unparalleled clinical importance and freedom from ascertain-
ment bias. However, as speciﬁc causes of death for each patient were
not uniformly available at all sites, the true proportion of deaths thatcould attributable to cardiovascular events in our patients is unknown.
Third, this study included a cohort of patients who were referred for
CCTA because of suspected CAD and were often symptomatic. Although
it is unlikely that our patient symptomswere related to non-obstructive
CAD, generalization of this study ﬁndings to asymptomatic patients re-
mains uncertain. Fourth, data on coronary calcium score were not in-
cluded in the analysis because they were available for two third only
of the study population.
5. Conclusion
The CT-adapted Leaman score is an independent predictor of major
acute cardiac events and allows to distinguish, among a population
with non-obstructive CAD, patients with risk of cardiac events similar
to those without plaques from patients with a less favorable prognosis.
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